A. Banerjee, A Simple Model of Herd Behavior, The Quarterly Journal of Economics, vol.107, issue.3, pp.797-817, 1992.
DOI : 10.2307/2118364

S. Callender, Bandwagons and Momentum in Sequential Voting, Review of Economic Studies, vol.74, issue.3, pp.653-684, 2007.
DOI : 10.1111/j.1467-937X.2007.00441.x

D. Carpenter, Reputation and Power: Organization Image and Pharmaceutical Regulation at the FDA, Conflicts of Interest on COX-2 Panel, 2005.
DOI : 10.1515/9781400835119

F. Chazel, Pouvoir, Traité de Sociologie, pp.195-226, 1992.

. Condorcet, « Essais sur la constitution et les fonctions des assemblées provinciales, Sur les Elections, 1986.

M. Crozier and E. Friedberg, Actors and Sytems :The Politics of Collective Action, 1980.

J. Elster, Explaining Social Behavior, 2007.
DOI : 10.1017/cbo9780511806421

J. Elster, Securities against Misrule: Juries, Assemblies, Elections, Cambridge, 2013.
DOI : 10.1017/CBO9781139382762

J. Gaudemet, Les élections dans l'Eglise latine, Des origines au XVIe siècle, 1990.

G. Harris and A. Berenson, 10 Voters on Panel Backing Pain Pills Had Industry Ties, 2005.

. Lurie, . Peter, C. M. Almeida, . Stine, . Nicholas et al., Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings, JAMA, vol.295, issue.16, pp.1921-1928, 2006.
DOI : 10.1001/jama.295.16.1921

M. A. Malone, Inside the FDA panel on Cox-2 inhibitors. More united than not, Stanford Medicine Magazine, vol.22, issue.2, 2005.

K. Mccomas, L. Tuit, and . Sherman, Conflicted scientists: the "shared pool" dilemma of scientific advisory committees, Public Understanding of Science, vol.14, issue.3, pp.285-303, 2005.
DOI : 10.1177/0963662505052891
URL : https://hal.archives-ouvertes.fr/hal-00571066

S. L. Moffitt, Promoting Agency Reputation through Public Advice: Advisory Committee Use in the FDA, The Journal of Politics, vol.72, issue.3, pp.3-880, 2010.
DOI : 10.1017/S002238161000023X

S. L. Moffitt, The Policiy Impact of Public Advice: The Effects of Advisory Committee Transparency on Regulatory Performance " , in C. Coglianese, Regulatory Breackdown? The Cirsis of Confidence in U.S. Regulation, 2012.

O. 'riordan and M. , Mistakes made : FDA acknowledges Lilly phoned to question Sanjay Kaul's inclusion on prasugrel panel, pp.23-26, 2009.

L. Quéré, « Les « dispositifs de confiance » dans l'espace public, pp.185-217, 2005.

P. Ricoeur, Freedom and nature: The voluntary and involuntary, 1966.

J. J. Rousseau, Lettres écrites de la montagne, ?1764?1964)

A. Tapley, . Lurie, . Peter, and S. Wolfe, Suboptimum use of FDA drug advisory committees, The Lancet, vol.368, issue.9554, p.2210, 1923.
DOI : 10.1016/S0140-6736(06)69892-9

P. Urfalino, Reasons and Preferences in Medicine Evaluation Committees, Collective Wisdom, pp.173-202, 2012.
DOI : 10.1017/CBO9780511846427.009

S. Usdin, FDA reviewing intellectual bias, BioCentury, 2009.

M. Warren, Democratic theory and trust, Democracy and Trust, 1999.
DOI : 10.1017/CBO9780511659959.011

D. M. Zuckerman, FDA Advisory Committees : Does Approval Mean Safety ?, 2006.